Tartephedreel oral drops sol. dropper cont. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tartephedreel oral drops sol. dropper cont.

heel belgium sa-nv - arsenum iodatum d6 10 g; lobelia inflata d4 5 g; illicium verum d3 5 g; naphthalinum d6 5 g; psychotria ipecacuanha d4 5 g; atropa bella-donna d4 10 g; natrum sulfuricum d4 10 g; kalium stibyltartaricum d4 10 g; blatta orientalis d6 5 g - oral drops, solution - illicium verum; kalium stibyltartaricum; arsenum iodatum; atropa bella-donna; natrum sulfuricum; blatta orientalis; psychotria ipecacuanha; lobelia inflata; naphthalinum

GASTROTONE- gentiana lutea, sambucus nigra, arsenicum album, kali bichromicum, lycopodium clavatum, phosphorus, pulsatilla bismu United States - English - NLM (National Library of Medicine)

gastrotone- gentiana lutea, sambucus nigra, arsenicum album, kali bichromicum, lycopodium clavatum, phosphorus, pulsatilla bismu

apotheca company - gentiana lutea root (unii: s72o3284ms) (gentiana lutea root - unii:s72o3284ms), sambucus nigra flowering top (unii: ct03bsa18u) (sambucus nigra flowering top - unii:ct03bsa18u), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), potassium dichromate (unii: t4423s18fm) (dichromate ion - unii:9lky4bfn2v), lycopodium clavatum spore (unii: c88x29y479) (lycopodium clavatum spore - unii:c88x29y479), phosphorus (unii: 27ylu75u4w) (phosphorus - unii:27ylu75u4w), pulsatilla vulgaris ( - gentiana lutea root 3 [hp_x] in 1 ml - indications:   for temporary relief of indigestion, nausea, retching, vomiting after eating or drinking, minor burning pain in the stomach. indications:   for temporary relief of indigestion, nausea, retching, vomiting after eating or drinking, minor burning in the stomach.

Arsenic trioxide medac European Union - English - EMA (European Medicines Agency)

arsenic trioxide medac

medac gesellschaft für klinische spezialpräparate mbh - arsenic trioxide - leukemia, promyelocytic, acute - antineoplastic agents - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.